Who are intramuscular paraldehyde's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sabril®, Butalbital, Aspirin And Caffeine, Brevital Sodium, pentothal sodium, Phenobarbital Sodium Injection, Etomidate Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intramuscular-paraldehyde.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

intramuscular paraldehyde — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

intramuscular paraldehyde (intramuscular paraldehyde) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Barbiturate. Area: Psychiatry.

phase 3 Barbiturate GABA transaminase Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

intramuscular paraldehyde (intramuscular paraldehyde) — Kamuzu University of Health Sciences. Paraldehyde is a sedative and anticonvulsant that acts by inhibiting the activity of GABA transaminase, leading to increased levels of GABA in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intramuscular paraldehyde TARGET	intramuscular paraldehyde	Kamuzu University of Health Sciences	phase 3	Barbiturate	GABA transaminase
Sabril®	Sabril®	Lundbeck LLC	marketed	GABA transaminase inhibitor	GABA transaminase (ABAT)
Butalbital, Aspirin And Caffeine	BUTALBITAL	Actavis Labs Ut Inc	marketed	Barbiturate [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2	1976-01-01
Brevital Sodium	METHOHEXITAL	Ph Health	marketed	Barbiturate	GABA-A receptor alpha-1/beta-3/gamma-2	1960-01-01
pentothal sodium	pentothal sodium	Ajou University School of Medicine	marketed	Barbiturate	GABA-A receptor
Phenobarbital Sodium Injection	Phenobarbital Sodium Injection	PharPoint Research, Inc.	marketed	Barbiturate	GABA-A receptor
Etomidate Injection	Etomidate Injection	Korea University Anam Hospital	marketed	Non-barbiturate hypnotic; GABA-A receptor positive allosteric modulator	GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Barbiturate class)

Ajou University School of Medicine · 1 drug in this class
Kamuzu University of Health Sciences · 1 drug in this class
Ph Health · 1 drug in this class
PharPoint Research, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). intramuscular paraldehyde — Competitive Intelligence Brief. https://druglandscape.com/ci/intramuscular-paraldehyde. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing